BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant ...

BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $207 from $190 and keeps a Neutral rating on the shares as ...

Becton, Dickinson and Company (NYSE:BDX) is included among the 12 Best Income Stocks to Buy Now. On December 17, RBC Capital ...

William Blair starts coverage on Waters with an Outperform rating, saying the BD merger could drive strong earnings growth and about 20% upside as investor confidence improves.

(Reuters) - Becton Dickinson reported a better-than-expected third-quarter profit on Thursday, helped by strong demand for its drug-delivery devices. Medical technology firms such as Becton, Boston ...

The US$205 analyst price target for BDX is 37% less than our estimate of fair value In this article we are going to estimate ...

Throughout the last three months, 5 analysts have evaluated Becton Dickinson (NYSE:BDX), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of ...

This was the stock's second consecutive day of gains.

Becton Dickinson, and Company (NYSE:BDX) lowered its fiscal year 2025 guidance and provided an estimated tariff impact on Thursday. The medical device company reported adjusted earnings per share of ...

Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically aligned entities. He stated ...

6 analysts have shared their evaluations of Becton Dickinson (NYSE:BDX) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table provides a quick ...

The stock's fall snapped a three-day winning streak.